Roche is bringing back gantenerumab from the dead, taking another stab at Alzheimer’s PhIII
Alzheimer’s drugs are expensive to test and unlikely to succeed, but they are also hard to kill.
More than two years after gantenerumab failed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
